It is a well-characterized, mechanistically specific peptide with a 30-year research history, a strong clinical safety record from formal trials, and modest but real efficacy data from 12-week studies
(85 g) provides 93% of the DV (22,27)
The high demand for semaglutide and tirzepatide has led to an increase in the availability of many non-FDA-approved compounded peptides
Dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, which means it mimics the action of these incretin hormones to enhance insulin secretion, suppress glucagon release, and slow gastric emptying
Pregnancy and lactation: Safety is not yet clear
When picking a clinic, look for one thats well-known and has experience with HCG weight loss